5,8-dihydroxy-4,7-diazaspiro[2.5]octane-4,7-dicarboxylic acid di-tert-butyl ester | 1012781-80-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5,8-dihydroxy-4,7-diazaspiro[2.5]octane-4,7-dicarboxylic acid di-tert-butyl ester
• 英文别名: Di-tert-butyl 5,8-dihydroxy-4,7-diazaspiro[2.5]octane-4,7-dicarboxylate；ditert-butyl 5,8-dihydroxy-4,7-diazaspiro[2.5]octane-4,7-dicarboxylate
• CAS: 1012781-80-4
• 化学式: C₁₆H₂₈N₂O₆
• 分子量: 344.408
• InChiKey: LNYQBHBDQIGAOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  99.5
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5,8-dihydroxy-4,7-diazaspiro[2.5]octane-4,7-dicarboxylic acid di-tert-butyl ester 在 三乙基(硅烷-d) 、 三氟化硼乙醚 作用下， 生成
  参考文献：
  名称：

  An unexpected aminocyclopropane reductive rearrangement

  摘要：

  A reductive rearrangement of aminocyclopropanes is described for the synthesis of cis- or trans-fused bicyclic 1,2-diaminocyclobutanes. Ionization of a cyclic aminal using BF(3)center dot OEt(2) induces rearrangement to a cyclobutyl iminium ion, which is subsequently reduced by Et(3)SiH. Substitution with allyltrimethylsilane allows carbon incorporation, giving a quaternary center. Silyloxy-substituted cyclopropanes rearrange rapidly to cyclobutanones which react with NaBH(4) to provide 1,2-aminohydroxycyclobutanes. These aminals were generated by the reduction of a Boc-imide with DIBAL-H or LiBH(4). (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2007.12.054
• 作为产物：
  描述：

  4,7-二氮杂螺[2.5]辛烷-5,8-二酮 在 4-二甲氨基吡啶 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 5,8-dihydroxy-4,7-diazaspiro[2.5]octane-4,7-dicarboxylic acid di-tert-butyl ester
  参考文献：
  名称：

  含氮环类衍生物调节剂、其制备方法和应用

  摘要：

  本发明涉及含氮环类衍生物调节剂、其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为G蛋白耦联受体调节剂在治疗或预防中枢神经系统疾病和/或精神疾病的用途。

  公开号：

  CN112778183A

文献信息

• [EN] MULTICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS MULTICYCLIQUES
  申请人：[en]SLAP PHARMACEUTICALS LLC

  公开号：WO2023096915A1

  公开（公告）日：2023-06-01

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
• [EN] CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS<br/>[FR] CERTAINS 2,5-DIAZABICYCLO[4.2.0]OCTANES UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR GLP-1
  申请人：[en]ASTRAZENECA AB

  公开号：WO2023057427A1

  公开（公告）日：2023-04-13

  There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions, for example Type 2 diabetes.
• [EN] CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AND OCTAHYDROFURO[3,4- B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS<br/>[FR] CERTAINS 2,5-DIAZABICYCLO[4.2.0]OCTANES ET OCTAHYDROFURO[3,4-B]PYRAZINES UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR GLP-1
  申请人：[en]ASTRAZENECA AB

  公开号：WO2023057429A1

  公开（公告）日：2023-04-13

  There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I) and octahydrofuro[3,4-b]pyrazines, and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions, for example Type 2 diabetes.